ADIA, Sumeet Nagar’s hedge fund among anchor investors in Rossari Biotech’s IPO

By Ankit Doshi

  • 11 Jul 2020

Speciality chemicals maker Rossari Biotech Ltd has raised Rs 148.87 crore ($19.8 million) from a bunch of anchor investors including Abu Dhabi’s sovereign wealth fund and existing investor Malabar Investments.

Rossari allotted a little over 3.5 million shares at the upper end of the Rs 423-425 apiece price band to 15 investors, India’s largest manufacturer of textile specialty chemicals informed stock exchanges on Friday.

Abu Dhabi Investment Authority (ADIA) and Kotak Mahindra (International) Ltd each bought Rossari shares worth Rs 8.3 crore. Malabar India Fund bought shares worth Rs 14 crore.

Other investors include Ashoka India Opportunities Fund, Goldman Sachs India and existing backer IIFL Special Opportunities Fund.

Indian asset managers that subscribed to Rossari shares are HDFC Mutual Fund, SBI Mutual Fund, ICICI Prudential Fund, Mirae Asset Mutual Fund and Sundaram Mutual Fund.

HDFC Life Insurance Company was the sole insurer in the list of investors.

Anchor investors, also known as cornerstone investors, are institutions that accept a one-month lock-in for a sizeable allocation of shares. Their participation highlights investors’ confidence in an IPO and sets a benchmark for the investor community at large.

A little more than four months ago, Rossari had raised Rs 100 crore in a pre-IPO round by allotting shares to eight institutional investors including PE and hedge funds.

With the pre-IPO transaction, Rossari had managed to raise two-thirds of the fresh money it was otherwise aiming to mop up via the IPO when it filed its draft prospectus in December 2019.

At the time of filing, the IPO’s size was estimated at Rs 700 crore. Now, the IPO size stands at Rs 496.25 – excluding the pre-IPO round – at the upper end of the price band announced.

The company is now seeking a valuation of Rs 2,206 at the upper end of the price band as compared with an estimated Rs 2,681 crore it had sought at the time of its IPO filing seven months ago.

Rossari Biotech denied it had cut its valuation. “We… have not trimmed our valuations. In February 2020 we did our pre-IPO placement… at Rs 425 per share and even now our IPO is priced at Rs 425 per share,” the company said.

However, the company didn't clarify on its December 2019 estimated valuation.

The IPO comprises a sale of 5.25 million shares each by promoters Edward Menezes and Sunil Chari worth Rs 446 crore. The company also aims to raise Rs 50 crore in fresh capital. Rossari will use the fresh capital and the pre-IPO money to repay debt, fund working capital requirements and meet general corporate expenses.

A successful IPO will see Rossari join listed peers such as Aarti Industries Ltd, Vinati Organics Ltd, Atul Ltd as well as Galaxy Surfactants Ltd and Fine Organics Industries Ltd, both of which went public in 2018.

Axis Capital and ICICI Securities are merchant bankers arranging the share sale. Axcelus Finserv Pvt. Ltd is the adviser to the overall offer.

Rossari was originally incorporated as a partnership firm, Rossari Labtech, in March 2003. It makes specialty chemicals used as raw material in the FMCG, apparel, poultry and animal feed industries.

The company reported consolidated net profit of Rs 65.25 crore for the year ended March 2020 on operating revenue of Rs 603.81 crore. Its 2018-19 consolidated net profit was Rs 45.68 crore on revenue of Rs 517.12 crore.

Share article on